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SUMMARY: Tissue engineering technologies: just a quick note
about transplantation of bioengineered donor trachea and
augmentation cystoplasty by de novo engineered bladder tissue.
C. ALBERTI
Tissue engineering is a multidisciplinary scientific field that aims at
manufacturing in vitro biological substitutes to enhance or replace fai-
ling human organs. Various types of biodegradable synthetic polymer (poly-
glycolic acid, PGA; polylactic acid, PLA; polylactic-coglycolic acid), na-
turally-derived (alginate, collagen), acellular tissue-made up (small in-
testinal submucosa, SIS; acellular bladder submucosa, ABS) and com-
posite (PGA bound to collagen) materials have been used as scaffold for
either "unseeded" (cell-free) or "seeded" (autologous cells seeded onto the
matrix) tissue engineering strategies. The unseeded technique is directed
at promoting the in vivo tissue regenerative process, unfortunately with
certain limitations, whereas the "seeded technique" aims at creating in
vitro functional replacement tissues or organs. Recently, a decellularized
human dead donor trachea has been used as scaffold, that was then see-
ded, in vitro, by recipient epithelial cells and mesenchymal stem cell-de-
rived chondrocytes, to obtain a bioengineered airway to replace recipient's
failing left main bronchus. As far as clinical applications in Urology are
concerned, a cell-based approach (PGA-collagen composite scaffold see-
ded with autologous cells) has been achieved to successfully carry-out an
augmentation cystoplasty in subjects with end-stage neuropathic high pres-
sure/poorly compliant bladder. The use of autologous cells, wherein a spe-
cimen of tissue is harvested by biopsy from the host, avoids the risk of rejec-
tion. Nevertheless, the use of adult organ-specific cells shows many limi-
tations, such as difficulties in their harvesting (potential complications
associated with invasive biopsies) and their low proliferative ability. The-
refore, various populations of either embryonic or adult stem cells and
progenitor cells have been studied as useful cell sources for the tissue en-
gineering. Bioreactors are essential in such technologies, both providing
chemo-physical cell culture dynamic conditions, that mimic the in vivo
environment, and allowing the assessment of responses of biological sub-
stitutes to different biochemical signals and mechanical forces.
RIASSUNTO: Tecnologie di ingegneria tessutale: breve nota su
trapianto di trachea da donatore bioingegnerizzata e cistoplastica
di ampliamento mediante tessuto vescicale ingegnerizzato de novo.
C. ALBERTI
Per ingegneria dei tessuti si intende un settore scientifico multidisci-
plinare volto alla realizzazione in vitro di strutture biologiche di ricambio,
atte a rinforzare o sostituire organi umani in precarie condizioni. Di-
versi tipi di materiali – quali polimeri sintetici biodegradabili (acido po-
liglicolico, PGA; acido polilattico, PLA; copolimero PGA-PLA), sostan-
ze di derivazione naturale (alginato, collagene), matrici acellulari (sub-
mucosa del piccolo intestino, SIS; submucosa acellulare vescicale, ABS),
o tra loro assemblati (PGL legato a collagene) – sono stati impiegati co-
me intelaiature (scaffold) sia prive di cellule ("unseeded technique"), al-
lo scopo di promuovere, in vivo, nell'organo in cui vengono impiantate,
naturali processi rigenerativi, non sempre, però, attuantisi, sia per svi-
luppare, in vitro, previa semina, nella loro compagine, di cellule del po-
tenziale ricevente (autologous cell seeded technique), un tessuto ingegne-
rizzato, idoneo all'impiego in chirurgia ricostruttiva. Recentemente, la
trachea di donatore morto, opportunamente decellularizzata, è stata usa-
ta quale scaffold per essere seminata, in vitro, con cellule epiteliali e con-
drociti derivati da cellule staminali mesenchimali del ricevente, al fine
di ottenere un segmento ingegnerizzato di via respiratoria tale da sosti-
tuire il grosso bronco sinistro, gravemente malacico, del ricevente. In ri-
ferimento alle applicazioni in ambito urologico, è stato coronato da suc-
cesso l'impiego di una "seeded technique" (cellule autologhe seminate su
scaffold composto di PGA legato a collagene) per confezionare tessuto in-
gegnerizzato vescicale usato nella realizzazione di cistoplastica d'am-
pliamento in soggetti affetti da "vescica neurologica", ormai in fase estre-
mamente grave (livelli alti di pressione endovescicale, compliance vesci-
cale molto ridotta). L'impiego di cellule autologhe, ottenute, mediante
biopsia, dai tessuti del ricevente, evita il rischio di rigetto dopo l'impianto.
Peraltro, il ricorso a cellule organo-specifiche "adulte" presenta dei limi-
ti correlati alla loro raccolta (potenziali complicazioni associate all'in-
vasività della biopsia) ed alle difficoltà di cultura in vitro data la loro
bassa capacità proliferativa. Pertanto, sono stati presi in considerazione
diversi tipi di cellule staminali, embrionali o adulte, e di cellule proge-
nitrici, al fine di utilizzarle in ingegneria dei tessuti. Per queste tecno-
logie risulta indispensabile l'impiego di bioreattori, atti a riprodurre, nel-
le culture cellulari, le condizioni dinamiche chimico-fisiche proprie del-
l'ambiente tissutale naturale, ed a consentire la valutazione delle rispo-
ste delle strutture bioingegnerizzate a differenti segnali biochimici e for-
ze meccaniche.
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Regenerative medicine is a fast-evolving polydiscipli-
nary scientific field – including materials science, cell cul-
ture, therapeutic cloning, stem cells and engineering – that
aims at manufacturing functional biological structures to
regenerate and enhance failing organs or create biologi-
cal replacement substitutes (1-6).
Tissue engineering technologies may use as scaffold
either biodegradable synthetic polymers such as polyg-
lycolic acid (PGA), polylactic acid (PLA), polylactic-
coglycolic acid, sometimes bound to collagen matrix
(composite scaffold), or naturally-derived materials  like
alginate and collagen or, moreover, acellular tissue ma-
trices as small intestinal submucosa (SIS) and acellular
bladder submucosa (ABS). Current strategies include ei-
ther unseeded or seeded techniques, the first directed to
promote, by incorporating a cell-free scaffold into a dis-
eased organ, the in vivo tissue regenerative process (re-
generative medicine), whereas the second, by using re-
cipient cells seeded onto a scaffold, aims at generating,
in vitro, functional replacement tissues or organs, thus
carrying out a properly named tissue engineering (7-14).
Just intriguingly, a decellularized donor organ (trachea)
has been recently used as ready made organ-shaped ma-
trix scaffold to be seeded with recipient cells, so that to
remplace a damaged organ (bronchus) (15, 16). Such
technique is here compared with the tissue engineering
using a cell-seeded composite scaffold to carry-out an
augmentation cystoplasty (17, 18).
Transplantation of bioengineered
donor trachea
Over the last two decades, many attemps have been
carried out to construct tracheal spare parts to be used in
different tracheal pathological conditions such as either con-
genital abnormalities (atresia, fistulas) or acquired diseases
(chronic inflammatory stenosis, tumor invasion, etc), but
they have met with serious difficulties (15, 16, 19-21).
In an animal model, a tissue-engineered tracheal
equivalent – tubular  cartilage  tissue  lined with recip-
ient nasal  epithelial cells – has been manufactured but
unfortunately it proved  to be easily collapsable (22, 23).
In other animal experimentations, donor tracheal ma-
trix, obtained by decellularizing the native donor organ
with a detergent-enzymatic (deoxyribonuclease, DNase)
treatment to decrease its major histocompatibility  com-
plex (MHC)antigens,  was able to support  in vitro the
adhesion and growth of both chondrocytes  and  tracheal
epithelial cells harvested from recipient animal, thus pro-
posing an alternative approach to repair or replace  tra-
cheal  defects (24, 25).
The first clinical application of a bioengineered airway
patch, made from autologous muscle cells and fibroblasts
seeded onto collagen-matrix, has been successfully carried
out to repair an airway defect, measuring 2x2 cm, oc-
curring at the anastomotic site after carinal pneumonec-
tomy and, most interestingly, such tissue-engineered patch
was reseeded in vivo by ciliated respiratory epithelium (16).
Subsequently, a transplantation of bioengineered airway seg-
ment has been performed in 30-year-old woman with post-
tubercolous chronic tracheitis and left main bronchus end-
stage malacia,  by using, as a ready made organ-schaped
scaffold, a human dead donor trachea. This explant, at
first, was decellularized by a detergent-enzymatic method,
to achieve the complete removal of donor MHC antigens
and preserve only the underlying connective matrix, which
then was seeded in vitro with recipient mesenchymal stem
cell-derived chondrocytes and epithelial cells, so that to
obtain a living tissue construct to replace the recipient’s
diseased left main bronchus; the graft straight-away pro-
vided the patient with a functional airway, free from the
risks of rejection (Table 1) (15).
Apart from  that, in  the  field  of experimental heart
bioengineering, many attemps have been performed to
similarly obtain a tissue-engineered heart, by utilizing, in
animal models, a decellularized donor heart, whose pre-
serving the underlying extracellular matrix and reseed-
ing it with cardiac/endothelial cells; the  function of such
construct has been then tested  in a bioreactor to sim-
ulate the cardiac physiology (26, 27).
Bioreactors, also named biomimetic reactors, are es-
sential in tissue engineering technologies not only be-
cause they provide chemo-physical in vitro cell-culture
dynamic conditions (O2 and CO2 levels, pH, humidi-
ty, temperature, efficient nutrition, waste removal) sim-
ulating the in vivo environment, but also because they
enable a proper assessment of the responses of biologi-
cal substitutes – cell activity, differentiation and func-
tion – to various chemo-physical signals and different
mechanical strains (27-30).
Augmentation cystoplasty 
by de novo engineered bladder tissue
Congenital abnormalities and acquired diseases may
lead to bladder damage or loss, hence requiring aug-
KEY WORDS: Tissue engineering - Trachea - Bladder - Stem cells - Reconstructive Surgery - Urology.
Ingegneria tissutale - Trachea -Vescica - Cellule staminali - Chirurgia ricostruttiva - Urologia.
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mentation or replacement bladder reconstructive surgery,
whose gold standard still remains the use of bowel. How-
ever to prevent the problematic outcomes of the intes-
tinal prostheses systemic metabolic derangements
and/or pathomorphosic malignancies, particularly at the
uretero-intestinal anastomoses  and, moreover, consid-
ering that the prosthetic use of intestinal segments must
be avoid in some conditions such as the short gut syn-
drome and chronic inflammatory bowel disease, research
has been turned, over the last decades, on the develop-
ment of new strategies for more proper bladder recon-
struction. The at the end of past century emerging blad-
der tissue-engineering technologies include both unseeded
and seeded strategies, but, unfortunately, the cell free ma-
trices, rather than promote, in animal models, a natu-
ral  in vivo vesical wall regenerative process, showed , at
just one year of follow-up, a graft shrinkage (increased
wall collagen deposition, disorganized muscle develop-
ment, fibrosis) with bladder inadequate compliance (2,
7, 8, 10-12). The autologous cell seeded tissue engineering
technology, instead, allows the development of a blad-
der tissue that is able to mimic the functional ability of
smooth muscle wall together with displaying both bar-
rier and sensory transducer urothelial properties (Table
2).  In a canine cystoplasty model – subtotal trigone-
sparing cystectomy followed by wall replacement with
such engineered tissue – histological and immunocyto-
chemical analyses showed a normally organized graft wall
architecture, consisting of urothelial, suburothelial
connective and smooth muscle layers, and in vivo dy-
namic cystograms and in vitro contractility studies had
successful outcomes.  Moreover, serum chemistry, com-
plete blood count and electrolytes remained post-oper-
atively within normal levels, thus ruling out the signif-
icant systemic toxicity (7, 8, 10, 32).
Even smooth muscle cells engineered from func-
tionally abnormal extrophic and neuropathic bladder
showed both morphologic and dynamic normal features,
suggesting that smooth muscle cells from diseased organs
can be engineered in a healthy tissue (13, 17, 18, 32) 
Clinical validation of the concept of de novo bladder
tissue engineering with autologous cell seeded techni -
que – urothelial and smooth muscle recipient cells seed-
ed onto a collagen-polyglicolic composite three dimen-
sional scaffold – was successfully reached, by implanti-
ng such tissue engineered construct, with omental drap,
in patients requiring augmentation cystoplasty because
of end-stage neuropathic, myelomeningocele-related,
high-pressure poorly compliant bladder. Such cystoplasty
displayed normal trilayered architecture and both uro-
dynamic and renal function parameters remained with-
in physiologic ranges,  on a follow-up of longer than 8
years (17, 18, 33).
Nevertheless, considering that the current techniques
for tissue engineering depend upon a sample of autolo-
gous cells from the damaged recipient’s organ, the spec-
imens from a widely diseased organs may not yielt enough
healthy cells. Furthermore, other limitations – such as
potential complications associated with invasive tissue
biopsies and low in vitro proliferative ability of adult or-
gan-specific cells – have suggested the cell resort to oth-
er sources. Hence, promising chances of cell-based blad-
der engineering have been placed in the resort to pluri-
and multipotent stem cells, that are capable of self-renewal
TABLE 1 - TRANSPLANTATION OF THE BIOENGINEERED DONOR ORGAN ("AIRWAY MODEL").
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and differentiation in several tissue-specific cell lineages
(34-36). However, most current procedures to obtain
pluripotent embryonic  stem cells require the therapeuthic
cloning by nuclear transfer and the their harvesting from
blastocyst with embryo destruction, that meets with se-
rious ethical issues. To avoid these problems, various in-
triguing pathways have been tried, looking to alternative
sources of stem cells or progenitor cells: parthenogene-
sis-derived, from parthenogenetic activation of oocytes
(37, 38); ammiotic fluid and placenta-extracted (39); sper-
matogonial progenitor cells, from adult testis (40); adult
differentiated cell-derived stem cells, reprogramming so-
matic cells  by retrovirus-mediated introduction of four
genes (Oct3/4, Sox2, c-Myc and Klf4), thus obtaining
the so-called induced pluripotent  stem  cells, iPS (41, 42);
urine-derived progenitor cells with ability to differenti-
ate into several bladder lineages such as urothelial, smooth
muscle, endotelial, interstitial (43, 44).
TABLE 2 - DE NOVO RECONSTITUTION OF A FUNCTIONAL HOLLOW ORGAN BY TISSUE ENGINEERING ("BLAD-
DER MODEL").
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Conclusions
The intriguing transplantation of bioengineered donor
trachea concerns the use of a ready made organ-shaped
matrix scaffold, that is obtained by removing, through
a detergent-enzymatic treatment, every-type cells and
MHC antigens from the donor organ, thus preserving
the underlying extracellular matrix, which is seeded with
recipient cells to develop, inside a proper bioreactor, a
bioengineered organ to be implanted into the host (Table
1) (15, 16).
The tissue engineered bladder consists in a de novo
reconstitution of a functional tissue, including the hard-
working building of a three-dimensional scaffold, which
is then seeded with recipient cells (Table 2) (17, 18, 33).
Both technologies, by using autologous cells to be
seeded onto the anyway obtained scaffolds, allow to have
available immunologically “personalized” tissue-engi-
neered prostheses, therefore free from the risk of rejec-
tion after in vivo implantation, thus avoiding any im-
munosuppressive treatment.
Considering the dramatic advances, during little more
than one decade, in the field of tissue engineering, there
is to expect, looking to the near future, the achievement
of further intriguing goals.
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